Delivery Order SPE2DB20D9127-SPE2DB24FPRE8
Award Date
8/13/24
Potential Completion Date
9/4/24
Potential Value
$52K
Federal Agency
Defense Logistics Agency
Awardee
DMS Pharmaceutical Group Inc.
Ultimate Awardee
Not listed
NAICS Category
424210 - Drugs and Druggists' Sundries Merchant Wholesalers
PSC Category
6505 - Drugs And Biologicals
Federal Contract Vehicle
Set-Aside Type
No Set-Aside Used
Extent Competed
Full and Open Competition
Major Defense Program
Not listed
Pricing Type
Firm Fixed Price
Place of Performance
Park Ridge, IL 60068, USA
Solicitation Procedures
Negotiated Proposal / Quote
Number Of Offers Received
Not listed
Legislative Mandate
Not listed
National Interest Action
Not listed
Research Type
Not listed
Primary Consortia Member
Not listed
Similar Awards
This federal contract award, valued at $15,474.54, was issued by the Defense Logistics Agency (DLA) to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler, for the delivery of Tysabri 300 mg/15 ml vials. The contract is a firm fixed-price delivery order with no set-aside designation. It is part of DMS Pharmaceutical Group's larger indefinite delivery contract (IDC) with the DLA under the SPE2DB program, valued at up to $499,999,999, which runs through December...
This federal contract award was issued by the Defense Logistics Agency's (DLA) Medical Supply Chain division to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler. The $41,265.44 firm fixed-price delivery order is for the supply of TYSABRI 300 MG/15 ML vials to support the recurring medical needs of military health facilities. This award is part of a larger $499,999,999 indefinite delivery contract (IDC) between DMS Pharmaceutical Group and the DLA under the...
This federal contract award was issued by the Defense Logistics Agency (DLA) to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois. The $52,912.40 firm fixed-price delivery order is for the provision of TYSABRI 300 MG/15 ML VIAL 15ML, a specialized pharmaceutical product. This delivery order is part of a larger $499,999,999 Indefinite Delivery Contract (IDC) held by DMS Pharmaceutical Group with the DLA under the SPE2DB program....
This is a firm fixed-price delivery order awarded by the Defense Logistics Agency (DLA) to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois. The $25,547.76 contract is for the delivery of Tysabri 300 mg/15 ml vials. DMS Pharmaceutical Group holds a $499,999,999 Indefinite Delivery Contract (IDC) with the DLA under the SPE2DB program, which enables the DLA to issue delivery orders for a comprehensive range of pharmaceutical...
The U.S. government's Defense Logistics Agency (DLA) awarded a firm fixed-price delivery order contract valued at $10,316.36 to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois. The contract is for the supply of the drug Tysabri, a 300 mg/15 ml vial, to support the recurring medical supply needs of military health facilities worldwide. This delivery order contract is part of a larger $499,999,999 indefinite delivery contract...
This is a firm fixed-price delivery order awarded to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler, by the Defense Logistics Agency (DLA) under the SPE2DB procurement program. The contract is for $10,316.36 and covers the delivery of TYSABRI 300 MG/15 ML VIAL 15ML, with a period of performance through July 2, 2024. DMS Pharmaceutical Group holds a significant indefinite delivery contract (IDC) with the DLA, valued at up to $499,999,999, which runs...
This is a firm fixed-price delivery order awarded by the Defense Logistics Agency (DLA) to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler. The $52,627.70 contract is for the supply of Tysabri 300 mg/15 ml vials, with a performance period through April 28, 2025. DMS Pharmaceutical Group holds a larger $499,999,999 Indefinite Delivery Contract (IDC) with the DLA under the SPE2DB program, which enables the agency to issue delivery orders for a comprehensive...
This federal contract award to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler, was issued by the Defense Logistics Agency (DLA) under the Medical Supply Chain division. The $10,316.36 firm fixed-price delivery order covers the supply of Tysabri 300 mg/15 ml vial, with an ultimate completion date of October 31, 2024. This award is part of a larger $499,999,999 indefinite delivery contract (IDC) held by DMS Pharmaceutical Group to provide a comprehensive...
This is a firm fixed-price delivery order contract awarded by the Defense Logistics Agency (DLA) to DMS Pharmaceutical Group Inc., a woman-owned small business based in Park Ridge, Illinois. The contract, valued at $15,788.28, is for the delivery of TYSABRI 300 MG/15 ML VIAL 15ML pharmaceutical products. DMS Pharmaceutical Group holds a larger $499,999,999 Indefinite Delivery Contract (IDC) with the DLA under the SPE2DB program, which enables the agency to issue delivery orders for a wide...
This is a firm fixed-price delivery order awarded by the Defense Logistics Agency (DLA) to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois. The $5,158.18 order is for TYSABRI 300 MG/15 ML VIAL 15ML, a biologic medication. The order has a completion date of July 22, 2024. This delivery order is part of a larger indefinite delivery contract (IDC) valued up to $499,999,999 that DMS Pharmaceutical Group holds with the DLA under...